Journal article

Risk of Ovarian Cancer and the NF-kappa B Pathway: Genetic Association with IL1A and TNFSF10

Bridget Charbonneau, Matthew S Block, William R Bamlet, Robert A Vierkant, Kimberly R Kalli, Zachary Fogarty, David N Rider, Thomas A Sellers, Shelley S Tworoger, Elizabeth Poole, Harvey A Risch, Helga B Salvesen, Lambertus A Kiemeney, Laura Baglietto, Graham G Giles, Gianluca Severi, Britton Trabert, Nicolas Wentzensen, Georgia Chenevix-Trench, Alice S Whittemore Show all

CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2014

Grants

Awarded by European Community


Awarded by Cancer Research UK


Awarded by NIH


Awarded by Post-Cancer GWAS initiative


Awarded by Department of Defence


Awarded by Kathryn Sladek Smith


Awarded by US National Cancer Institute GAME-ON Post-GWAS Initiative


Awarded by Wellcome Trust


Awarded by American Cancer Society Early Detection Professorship


Awarded by Canadian Institutes of Health Research New Investigator award


Awarded by American Cancer Society


Awarded by California Cancer Research Program


Awarded by Canadian Institutes for Health Research


Awarded by Celma Mastry Ovarian Cancer Foundation the Danish Cancer Society


Awarded by Imperial Experimental Cancer Research Centre


Awarded by Polish Ministry of Science and Higher Education


Awarded by U.S. Army Medical Research and Materiel Command


Awarded by U.S. National Cancer Institute


Awarded by NIH/National Center for Research Resources/General Clinical Research Center


Awarded by U.S. Army Medical Research and Material Command


Awarded by National Health and Medical Research Council of Australia


Awarded by German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research


Awarded by state of Baden-Wurttembergthrough Medical Faculty of the University of Ulm


Awarded by Lon V. Smith Foundation



Funding Acknowledgements

Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175; COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C5047/A8384, C5047/A15007, C5047/A10692), the NIH (CA128978) and Post-Cancer GWAS initiative (No. 1 U19 CA 148537-the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.The OCAC is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of the data generated by the Wellcome Trust Case Control consortium. A full list of the investigators who contributed to the generation of the data is available at http://www.wtccc.org.uk/. Funding for the project was provided by the Wellcome Trust under award 076113.B. Charbonneau is supported by R25 CA92049. G. Chenevix-Trench and P.A. Fasching are supported by the Deutsche Krebshilfe. B.Y. Karlan holds an American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN). L.E. Kelemen is supported by a Canadian Institutes of Health Research New Investigator award (MSH-87734).Funding of the constituent studies was provided by the Minnesota Ovarian Cancer Alliance; the Mayo Foundation; the Fred C. and Katherine B. Andersen Foundation; the American Cancer Society (CRTG-00-196-01-CCE); the California Cancer Research Program (00-01389V-20170, N01-CN25403, 2II0200); the Canadian Institutes for Health Research (MOP-86727); Cancer Council Victoria; Cancer Council Queensland; Cancer Council New South Wales; Cancer Council South Australia; Cancer Council Tasmania; Cancer Foundation of Western Australia; the Cancer Institute of New Jersey; Cancer Research UK (C490/A6187, C490/A10119, C490/A10124, C536/A13086, C536/A6689); the Celma Mastry Ovarian Cancer Foundation the Danish Cancer Society (94-222-52); ELAN Funds of the University of Erlangen-Nuremberg; the Eve Appeal; the Helsinki University Central Hospital Research Fund; Sigrid Juselius Foundation; Imperial Experimental Cancer Research Centre (C1312/A15589); the Ovarian Cancer Research Fund; Nationaal Kankerplan of Belgium; the L & S Milken Foundation; the Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27); the Roswell Park Cancer Institute Alliance Foundation; the U.S. Army Medical Research and Materiel Command (W81XWH-07-1-0449); the U.S. National Cancer Institute (K07-CA80668, K07-CA095666, K07-CA143047, K22-CA138563, N01-CN55424, N01-PC067010, N01-PC035137, P01-CA017054, P01-CA087696, P30-CA072720, P50-CA105009, P50-CA136393, R01-CA014089, R01-CA016056, R01-CA017054, R01-CA049449, R01-CA050385, R01-CA054419, R01-CA058598, R01-CA058860, R01-CA061107, R01-CA061132, R01-CA063682, R01-CA064277, R01-CA067262, R01-CA071766, R01-CA074850, R01-CA076016, R01-CA080742, R01-CA080978, R01-CA087538, R01-CA092044, R01-095023, R01-CA106414, R01-CA122443, R01-CA112523, R01-CA114343, R01-CA126841, R01-CA149429, R03-CA113148, R03-CA115195, R37-CA070867, R37-CA70867, U01-CA069417, U01-CA071966, and Intramural research funds); NIH/National Center for Research Resources/General Clinical Research Center grant MO1-RR000056; the U.S. Army Medical Research and Material Command (DAMD17-98-1-8659, DAMD17-01-1-0729, DAMD17-02-1-0666, DAMD17-02-1-0669); the National Health and Medical Research Council of Australia (199600, 400281, 209057, 251533, 396414, 504715); the German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research (01 GB 9401); the state of Baden-Wurttembergthrough Medical Faculty of the University of Ulm (P.685); the Lon V. Smith Foundation (LVS-39420); the Oak Foundation; the OHSU Foundation; the Mermaid I project; the Rudolf-Bartling Foundation; the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, Imperial College London, University College London Hospital and the Royal Marsden Hospital; WorkSafeBC; Helse Vest, The Norwegian Cancer Society, The Research Council of Norway (HBS/NOR).